Mersana Therapeutics Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics or view top-rated stocks.

Wall Street analysts have given Mersana Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mersana Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Mersana Therapeutics.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its quarterly earnings data on Monday, May, 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.11. Mersana Therapeutics had a negative net margin of 12,779.23% and a negative trailing twelve-month return on equity of 44.42%.
View Mersana Therapeutics' earnings history.

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN shares have increased by 122.1% and is now trading at $14.35.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued 12 month price objectives for Mersana Therapeutics' stock. Their forecasts range from $18.00 to $33.00. On average, they expect Mersana Therapeutics' share price to reach $27.40 in the next twelve months. This suggests a possible upside of 90.9% from the stock's current price.
View analysts' price targets for Mersana Therapeutics or view top-rated stocks among Wall Street analysts.

3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Mersana Therapeutics include Arena Pharmaceuticals (ARNA), Alkermes (ALKS), Turning Point Therapeutics (TPTX), Arvinas (ARVN), Karuna Therapeutics (KRTX), Agios Pharmaceuticals (AGIO), Intra-Cellular Therapies (ITCI), Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), Cassava Sciences (SAVA), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Insmed (INSM), Taro Pharmaceutical Industries (TARO) and Cryoport (CYRX).
View all of MRSN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (11.59%), Sarissa Capital Management LP (5.76%), Price T Rowe Associates Inc. MD (4.28%), Bellevue Group AG (4.13%), Rock Springs Capital Management LP (3.99%) and Orbimed Advisors LLC (2.72%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics.

MRSN stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Acuta Capital Partners LLC, Price T Rowe Associates Inc. MD, Jane Street Group LLC, Nuveen Asset Management LLC, Ghost Tree Capital LLC, Schonfeld Strategic Advisors LLC, and Credit Suisse AG. Company insiders that have sold Mersana Therapeutics company stock in the last year include Ashish Mandelia, Eva M Jack, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics or view top insider-selling stocks.

MRSN stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sarissa Capital Management LP, Bellevue Group AG, Rock Springs Capital Management LP, CIBC Asset Management Inc, Citigroup Inc., Millennium Management LLC, and Putnam Investments LLC. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics or or view top insider-buying stocks.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRSN stock can currently be purchased for approximately $14.35.

Mersana Therapeutics has a market capitalization of $998.21 million and generates $830,000.00 in revenue each year. The company earns $-88,040,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

Mersana Therapeutics employs 110 workers across the globe.

The official website for Mersana Therapeutics is www.mersana.com.

Mersana Therapeutics is headquartered at 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]